Yumanity Therapeutics : VISTA blocking immunotherapy engineered to address immunosuppression in the tumor microenvironment (TME) Phase 1 initial data readout anticipated by end of 2023 - Form 8-K

(marketscreener.com) Kineta, Inc. , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the first patient has been dosed in a Phase 1/2 clinical study evaluating KVA12123 alone and in combination with the immune checkpoint inhibitor pembrolizumab in patients with...https://www.marketscreener.com/quote/stock/YUMANITY-THERAPEUTICS-117003859/news/Yumanity-Therapeutics-VISTA-blocking-immunotherapy-engineered-to-address-immunosuppression-in-the-43475181/?utm_medium=RSS&utm_content=20230412